

Amazon.com, Inc., 410 Terry Avenue North, Seattle, WA 98109.  
 Dell Technologies Inc., One Dell Way, Round Rock, TX 78682.  
 HP Inc., 1501 Page Mill Road, Palo Alto, CA 94304.  
 Lenovo Group Ltd., 6 Chuang ye Road, Haidian District, Beijing 100085 China.  
 Levono (United States) Inc., 1009 Think Place, Building One, Morrisville, NC 27560.  
 Microsoft Corporation, One Microsoft Way, Redmond, WA 98052.  
 Motorola Mobility LLC, 222 W. Merchandise Mart Plaza, Suite 1800, Chicago, IL 60654.  
 Samsung Electronics Co., Ltd., 129 Samsung-Ro, Maetab-3dong, Yeongtong-gu, Suwon, 443-742 South Korea.  
 Samsung Electronics America, Inc., 85 Challenger Rd., Ridgefield Park, NJ 07660.

(4) For the investigation so instituted, the Chief Administrative Law Judge, U.S. International Trade Commission, shall designate the presiding Administrative Law Judge.

The Office of Unfair Import Investigations will not be named as a party to this investigation.

Responses to the amended complaint and the notice of investigation must be submitted by the named respondents in accordance with section 210.13 of the Commission's Rules of Practice and Procedure, 19 CFR 210.13. Pursuant to 19 CFR 201.16(e) and 210.13(a), such responses will be considered by the Commission if received not later than 20 days after the date of service by the Commission of the amended complaint and the notice of investigation. Extensions of time for submitting responses to the amended complaint and the notice of investigation will not be granted unless good cause therefor is shown.

Failure of a respondent to file a timely response to each allegation in the amended complaint and in this notice may be deemed to constitute a waiver of the right to appear and contest the allegations of the amended complaint and this notice, and to authorize the administrative law judge and the Commission, without further notice to the respondent, to find the facts to be as alleged in the amended complaint and this notice and to enter an initial determination and a final determination containing such findings, and may result in the issuance of an exclusion order or a cease and desist order or both directed against the respondent.

By order of the Commission.

Issued: June 19, 2019.

**Lisa Barton,**

*Secretary to the Commission.*

[FR Doc. 2019-13379 Filed 6-21-19; 8:45 am]

**BILLING CODE 7020-02-P**

## JOINT BOARD FOR THE ENROLLMENT OF ACTUARIES

### Meeting of the Advisory Committee; Meeting

**AGENCY:** Joint Board for the Enrollment of Actuaries.

**ACTION:** Notice of Federal Advisory Committee meeting.

**SUMMARY:** The Joint Board for the Enrollment of Actuaries gives notice of a meeting of the Advisory Committee on Actuarial Examinations (portions of which will be open to the public) at the Internal Revenue Service, 1111 Constitution Avenue NW, Washington, DC, on July 11 and 12, 2019.

**DATES:** Thursday, July 11, 2019, from 9:00 a.m. to 5:00 p.m., and Friday, July 12, 2019, from 8:30 a.m. to 5:00 p.m.

**ADDRESSES:** The meeting will be held at the Internal Revenue Service; 1111 Constitution Avenue NW; Washington, DC 20224.

**FOR FURTHER INFORMATION CONTACT:** Ms. Elizabeth Van Osten, Designated Federal Officer, Advisory Committee on Actuarial Examinations, (202) 317-3648.

**SUPPLEMENTARY INFORMATION:** Notice is hereby given that the Advisory Committee on Actuarial Examinations will meet at the Internal Revenue Service; 1111 Constitution Avenue NW; Washington, DC 20224, on Thursday, July 11, 2019, from 9:00 a.m. to 5:00 p.m., and Friday, July 12, 2019, from 8:30 a.m. to 5:00 p.m.

The purpose of the meeting is to discuss topics and questions that may be recommended for inclusion on future Joint Board examinations in actuarial mathematics and methodology referred to in 29 U.S.C. 1242(a)(1)(B) and to review the May 2019 Pension (EA-2L) and Basic (EA-1) Examinations in order to make recommendations relative thereto, including the minimum acceptable pass scores. Topics for inclusion on the syllabus for the Joint Board's examination program for the November 2019 Pension (EA-2F) Examination will be discussed.

A determination has been made as required by section 10(d) of the Federal Advisory Committee Act, 5 U.S.C. App., that the portions of the meeting dealing with the discussion of questions that may appear on the Joint Board's

examinations and the review of the May 2019 EA-2L and EA-1 Examinations fall within the exceptions to the open meeting requirement set forth in 5 U.S.C. 552b(c)(9)(B), and that the public interest requires that such portions be closed to public participation.

The portion of the meeting dealing with the discussion of the other topics will commence at 1:00 p.m. on July 11, 2019, and will continue for as long as necessary to complete the discussion, but not beyond 3:00 p.m. Time permitting, after the close of this discussion by Committee members, interested persons may make statements germane to this subject. Persons wishing to make oral statements should notify the Joint Board in writing prior to the meeting in order to aid in scheduling the time available and should submit the written text, or at a minimum, an outline of comments they propose to make orally. Such comments will be limited to 10 minutes in length. All persons planning to attend the public session should notify the Joint Board in writing to obtain building entry. Notifications of intent to make an oral statement or to attend must be sent electronically, by no later than July 3, 2019, to [NHQBEA@irs.gov](mailto:NHQBEA@irs.gov). In addition, any interested person may file a written statement for consideration by the Joint Board and the Committee by sending it to: Ms. Elizabeth Van Osten; Joint Board for the Enrollment of Actuaries; SE:RPO, Room 3422; 1111 Constitution Avenue NW, Washington, DC 20224.

Dated: June 18, 2019.

**Thomas V. Curtin, Jr.,**

*Executive Director, Joint Board for the Enrollment of Actuaries.*

[FR Doc. 2019-13365 Filed 6-21-19; 8:45 am]

**BILLING CODE 4830-01-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[Docket No. DEA-392]

#### Importer of Controlled Substances Application: VHG Labs DBA LGC Standards

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before July 24, 2019. Such persons may also file a written request for a hearing on the application on or before July 24, 2019.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701

Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.34(a), this is notice that on March 6, 2019, VH

Labs DBA LGC Standards, 3 Perimeter Road, Manchester, New Hampshire 03103 applied to be registered as an importer of the following basic classes of controlled substances:

Controlled substance	Drug code	Schedule
Cathinone	1235	I
Methcathinone	1237	I
Naphyrone	1258	I
N-Ethylamphetamine	1475	I
JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole)	6250	I
SR-18 (Also known as RCS-8) (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole)	7008	I
APINACA and AKB48 N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide	7048	I
JWH-081 (1-Pentyl-3-(1-(4-methoxynaphthoyl)indole)	7081	I
SR-19 (Also known as RCS-4) (1-Pentyl-3-[(4-methoxy)-benzoyl]indole)	7104	I
JWH-018 (also known as AM678) (1-Pentyl-3-(1-naphthoyl)indole)	7118	I
JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole)	7122	I
UR-144 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone	7144	I
JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole)	7203	I
Ibogaine	7260	I
Lysergic acid diethylamide	7315	I
Marihuana	7360	I
Mescaline	7381	I
3,4-Methylenedioxymethamphetamine	7405	I
5-Methoxy-N-N-dimethyltryptamine	7431	I
Psilocyn	7438	I
4-Methyl-alpha-pyrrolidinopropiophenone (4-MePPP)	7498	I
Methylone (3,4-Methylenedioxy-N-methylcathinone)	7540	I
Butylone	7541	I
Pentylone	7542	I
Codeine-N-oxide	9053	I
Desomorphine	9055	I
Dihydromorphine	9145	I
Heroin	9200	I
Morphine-N-oxide	9307	I
Normorphine	9313	I
Tilidine	9750	I
Alpha-methylfentanyl	9814	I
Methamphetamine	1105	II
Phenmetrazine	1631	II
Amobarbital	2125	II
Pentobarbital	2270	II
Secobarbital	2315	II
Glutethimide	2550	II
Phencyclidine	7471	II
Phenylacetone	8501	II
Dihydrocodeine	9120	II
Diphenoxylate	9170	II
Ecgonine	9180	II
Ethylmorphine	9190	II
Levorphanol	9220	II
Meperidine	9230	II
Meperidine intermediate-B	9233	II
Meperidine intermediate-C	9234	II
Dextropropoxyphene, bulk (non-dosage forms)	9273	II
14-Hydroxymorphone	9665	II
Noroxymorphone	9668	II
Sufentanil	9740	II

The company plans to import analytical reference standards for distribution to its customers for research and analytical purposes. Placement of these drug codes onto the company's registration does not translate into automatic approval of subsequent permit applications to import controlled substances. Approval of permit applications will occur only when the registrant's business activity is

consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of FDA approved or non-approved finished dosage forms for commercial sale.

Dated: June 6, 2019.

**John J. Martin,**  
Assistant Administrator.

[FR Doc. 2019-13377 Filed 6-21-19; 8:45 am]

**BILLING CODE 4410-09-P**

## DEPARTMENT OF JUSTICE

### Notice of Extension of Comment Period of Proposed Consent Decree Under the Clean Water Act

On May 17, 2019, the Department of Justice lodged a proposed consent decree with the United States District Court for the Western District of Washington in the lawsuit entitled